Daré Bioscience (DARE) Q2 2025 earnings summary

Executive summary

• Accelerated dual-path strategy focuses on commercializing proprietary formulations via 503(b) compounding and pursuing FDA approval, with expansion into branded consumer health products and partnerships for commercialization.

• DARE to PLAY Sildenafil Cream is on track for Q4 2025 launch via 503(b) compounding, with near-term revenue expected; Ovaprene Phase 3 trial is progressing with positive interim DSMB results.

• Portfolio targets unmet needs in women's health, including contraception, sexual health, HPV, preterm birth, pelvic pain, fertility, infectious disease, vaginal health, and menopause.

• Multiple grant-funded programs are advancing, such as DARE-HPV and DARE-LARC1, with four women's health solutions anticipated, including vaginal probiotics and hormone therapy.

• XACIATO, the first FDA-approved product, is marketed by Organon; rights to future royalties and milestones were sold to XOMA in April 2024.

Financial highlights

• Ended Q2 2025 with $5.0 million in cash and cash equivalents and a working capital deficit of $12.6 million.

• Post-quarter, $17.6 million was raised via stock sales and a $6.0 million grant was received, strengthening liquidity.

• Net loss for Q2 2025 was $4.0 million, compared to net income of $12.9 million in Q2 2024, mainly due to the absence of one-time royalty sale income.

• R&D expenses decreased 71% year-over-year to $1.4 million, reflecting increased grant offsets and lower manufacturing and development costs.

• G&A expenses were $2.4 million, down from $2.5 million in Q2 2024.

Outlook and guidance

• DARE to PLAY Sildenafil Cream is expected to launch in Q4 2025, with product revenue anticipated to begin the same quarter; DARE-HRT1 is targeted for late 2026 via a similar dual-path approach.

• Additional capital is required to advance pipeline programs not supported by grants, though recent equity raises and grants mitigate near-term liquidity risk.

• Two non-prescription vaginal probiotics are planned to launch after DARE to PLAY, expanding the consumer health portfolio.

• Continued advancement of grant-funded programs, with DARE-LARC1 preclinical development fully funded.

• Substantial doubt remains about ability to continue as a going concern over the next 12 months without further capital.